Press Releases

NEWPORT NEWS, Va., Feb. 10, 2012 (GLOBE NEWSWIRE) -- Huntington Ingalls Industries (NYSE: HII) today hosted a visit by U.S. Reps. Joe Courtney (D-Conn.) and Robert C. Scott (D-Va.) at the company's Newport News Shipbuilding (NNS) division.

A photo accompanying this release is available at http://media.globenewswire.com/hii/mediagallery.html?pkgid=11624 The congressmen met with shipbuilders during tours of the aircraft carrier Gerald R. Ford (CVN 78), which is currently under construction, the aircraft carrier USS Theodore Roosevelt (CVN 71), which is undergoing its mid-life refueling and complex overhaul (RCOH), and Newport News' submarine construction facilities. They also observed a demonstration of the virtual design tool being used to design Ford-class carriers.

"It's important that our country's decision-makers see the pride and precision that go into our products," said NNS President Matt Mulherin. "Both congressmen have lent tremendous support to shipbuilding, and we appreciate their continued efforts."

As a member of the House Armed Services Committee (HASC), Courtney serves on the Seapower and Projection Forces and the Military Readiness subcommittees. He co-chairs the Congressional Shipbuilding Caucus with Rep. Rob Wittman (R-Va.) and played an instrumental role in securing funding for the Virginia-class submarine program's two-submarines-per-year build plan.

"Thank you to Congressman Bobby Scott for taking the time today to host me at the Newport News shipyard," Courtney said. "As a member of the House Armed Services Committee's Seapower Subcommittee and the co-chairman of the Congressional Shipbuilding Caucus, I appreciate the opportunity to see the work being done in Virginia in support of the Navy. The submarines being built here and in Groton, Conn., are critical to our national security as the Pentagon shifts to a leaner, more agile force focused increasingly on the Pacific."

Among the committees on which Rep. Scott serves is the Committee on the Judiciary, where he is the ranking member of the Subcommittee on Crime, Terrorism and Homeland Security and a member of the Subcommittee on the Constitution.

"Newport News Shipbuilding and the men and women who work here are one of our nation's most critical national security assets," Scott said. "I was honored to have the opportunity to help show my friend and colleague, Congressman Joe Courtney, around the shipyard. As co-chair of the Congressional Shipbuilding Caucus, Congressman Courtney is a strong leader and advocate for shipbuilding. I look forward to continuing to work with Congressman Courtney to ensure that shipbuilding remains one of our top defense priorities."

Huntington Ingalls Industries (HII) designs, builds and maintains nuclear and non-nuclear ships for the U.S. Navy and Coast Guard and provides after-market services for military ships around the globe. For more than a century, HII has built more ships in more ship classes than any other U.S. naval shipbuilder. Employing nearly 38,000 in Virginia, Mississippi, Louisiana and California, its primary business divisions are Newport News Shipbuilding and Ingalls Shipbuilding. For more information, visit:

• HII on the web: www.huntingtoningalls.com
• HII on Facebook: www.facebook.com/HuntingtonIngallsIndustries
• HII on Twitter: twitter.com/hiindustries

The Huntington Ingalls Industries, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=9418  

CONTACT: Christie Miller
         Christine.Miller@HII-co.com
         (757) 380-3581

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 14th Annual BIO CEO & Investor Conference on Tuesday, February 14, 2012 at 3:30 p.m. ET and at the Leerink Swann 2012 Global Healthcare Conference on Wednesday, February 15, 2012 at 3:30 p.m. ET, both being held at the Waldorf=Astoria in New York City.

Live audio webcasts of the presentations will be available on the News & Investors section of the company’s website, www.alnylam.com. A replay of the presentations will be available on the Alnylam website within 48 hours after the events.

About Alnylam Pharmaceuticals

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases, including ALN-TTR for the treatment of transthyretin-mediated amyloidosis (ATTR), ALN-PCS for the treatment of severe hypercholesterolemia, ALN-HPN for the treatment of refractory anemia, ALN-APC for the treatment of hemophilia, and ALN-TMP for the treatment of hemoglobinopathies. As part of its “Alnylam 5x15TM” strategy, the company expects to have five RNAi therapeutic products for genetically defined diseases in clinical development, including programs in advanced stages, on its own or with a partner by the end of 2015. Alnylam has additional partner-based programs in clinical or development stages, including ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection, ALN-VSP for the treatment of liver cancers, and ALN-HTT for the treatment of Huntington’s disease. The company’s leadership position on RNAi therapeutics and intellectual property have enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko Kirin, and Cubist. In addition, Alnylam and Isis co-founded Regulus Therapeutics Inc., a company focused on discovery, development, and commercialization of microRNA therapeutics; Regulus has formed partnerships with GlaxoSmithKline and Sanofi. Alnylam has also formed Alnylam Biotherapeutics, a division of the company focused on the development of RNAi technologies for applications in biologics manufacturing, including recombinant proteins and monoclonal antibodies. Alnylam’s VaxiRNA™ platform applies RNAi technology to improve the manufacturing processes for vaccines; GlaxoSmithKline is a collaborator in this effort. Alnylam scientists and collaborators have published their research on RNAi therapeutics in over 100 peer-reviewed papers, including many in the world’s top scientific journals such as Nature, Nature Medicine, Nature Biotechnology, and Cell. Founded in 2002, Alnylam maintains headquarters in Cambridge, Massachusetts. For more information, please visit www.alnylam.com.

Alnylam Pharmaceuticals, Inc.InvestorsCynthia Clayton, 617-551-8207orMediaSpectrumAmanda Sellers, 202-955-6222 x2597

Source: Alnylam Pharmaceuticals, Inc.

ROCKVILLE, Md.--(BUSINESS WIRE)-- Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its presentation at the 14th Annual BIO CEO & Investor Conference will be webcast and may be accessed at www.hgsi.com.

A member of Human Genome Sciences’ senior management team will present a corporate overview on Tuesday, February 14, 2012, at 11:30 AM Eastern time. Investors interested in listening to the live webcast may want to log on before the presentation begins to download any software required. The archive of the presentation will be available for several days following the event.

ABOUT HUMAN GENOME SCIENCES

Human Genome Sciences exists to place new therapies into the hands of those battling serious disease.

For more information about HGS, please visit the Company’s web site at www.hgsi.com. Health professionals and patients interested in clinical trials of HGS products may inquire via e-mail to clinicaltrialsinfo@hgsi.com or by calling HGS at (240) 314-4430.

HGS and Human Genome Sciences are trademarks of Human Genome Sciences, Inc. Other trademarks referenced are the property of their respective owners.

Human Genome Sciences, Inc.Media Contacts:Susannah BudingtonDirector, Corporate Public Relations301-545-1062orJerry ParrottVice President, Corporate Communications301-315-2777orInvestor Contacts:Claudine Prowse, Ph.D.Executive Director, Investor Relations301-315-1785orPeter VozzoSenior Director, Investor Relations301-251-6003

Source: Human Genome Sciences, Inc.